TGTomás Gutiérrez

Tomás Gutiérrez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tomás Gutiérrez has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Mario Chiong

    Advanced Center for Chronic Diseases (ACCDiS), Facultad Ciencias Quimicas y Farmaceuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile

    5 shared publications
  • Sergio Lavandero

    Advanced Center for Chronic Diseases (ACCDiS), Facultad de Ciencias Quimicas y Farmaceuticas & Facultad de Medicina, Universidad de Chile, Santiago, 8380494, Chile; Núcleo de Biología y Genética (NiBG), Instituto de Ciencias Biomedicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, 8330351, Chile; Cardiology Division, Harry S. Moss Heart Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390-9047, USA

    4 shared publications
  • Valentina Parra

    Centro de biología de sistemas para el estudio de comunidades extremófilas de relaves mineros (SYSTEMIX), Universidad de O’Higgins

    4 shared publications
  • Andrea del Campo

    Laboratorio de Fisiología y Bioenergética Celular (LABFBE), Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Chile

    3 shared publications
  • Beverly A. Rothermel

    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, USA

    3 shared publications
  • Pablo E. Morales

    Advanced Center for Chronic Diseases (ACCDiS)-CEMC, Facultad Ciencias Químicas y Farmacéuticas y Facultad Medicina, Santiago, Chile

    3 shared publications

Latest Publications

  • Open Access

    The non-cytotoxic small molecule NPB does not inhibit BAD phosphorylation and forms colloidal aggregates

    by John Maringa Githaka, Tomás Gutiérrez, Zhuang Zhuang Han, Joseph O. Primeau, Heather Muranyi, Howard S. Young, Brian D. Sykes, Olivier Julien, Ing Swie Goping


  • The ER chaperone calnexin controls mitochondrial positioning and respiration

    by Tomás Gutiérrez, Hong Qi, Megan C. Yap, Nasser Tahbaz, Leanne A. Milburn, Eliana Lucchinetti, Phing-How Lou, Michael Zaugg, Paul G. LaPointe, Pascal Mercier, et al.

    Control of Ca 2+ flow from the ER to mitochondria by calnexin balances output from energy production pathways.


  • Open Access

    TMX1 determines cancer cell metabolism as a thiol-based modulator of ER–mitochondria Ca2+ flux

    by Arun Raturi, Tomás Gutiérrez, Carolina Ortiz-Sandoval, Araya Ruangkittisakul, Maria Sol Herrera-Cruz, Jeremy P. Rockley, Kevin Gesson, Dimitar Ourdev, Phing-How Lou, Eliana Lucchinetti, et al.

    The flux of Ca2+ from the endoplasmic reticulum (ER) to mitochondria regulates mitochondria metabolism. Within tumor tissue, mitochondria metabolism is frequently repressed, leading to chemotherapy resistance and increased growth of the tumor mass. Therefore, altered ER–mitochondria Ca2+ flux could be a cancer hallmark, but only a few regulatory proteins of this mechanism are currently known. One candidate is the redox-sensitive oxidoreductase TMX1 that is enriched on the mitochondria-associated membrane (MAM), the site of ER–mitochondria Ca2+ flux. Our findings demonstrate that cancer cells with low TMX1 exhibit increased ER Ca2+, accelerated cytosolic Ca2+ clearance, and reduced Ca2+ transfer to mitochondria. Thus, low levels of TMX1 reduce ER–mitochondria contacts, shift bioenergetics away from mitochondria, and accelerate tumor growth. For its role in intracellular ER–mitochondria Ca2+ flux, TMX1 requires its thioredoxin motif and palmitoylation to target to the MAM. As a thiol-based tumor suppressor, TMX1 increases mitochondrial ATP production and apoptosis progression.


  • Open Access

    Alteration in mitochondrial Ca2+ uptake disrupts insulin signaling in hypertrophic cardiomyocytes

    by Tomás Gutiérrez, Valentina Parra, Rodrigo Troncoso, Christian Pennanen, Ariel Contreras-Ferrat, César Vasquez-Trincado, Pablo E Morales, Camila Lopez-Crisosto, Cristian Sotomayor-Flores, Mario Chiong, et al.

    Cardiac hypertrophy is characterized by alterations in both cardiac bioenergetics and insulin sensitivity. Insulin promotes glucose uptake by cardiomyocytes and its use as a substrate for glycolysis and mitochondrial oxidation in order to maintain the high cardiac energy demands. Insulin stimulates Ca2+ release from the endoplasmic reticulum, however, how this translates to changes in mitochondrial metabolism in either healthy or hypertrophic cardiomyocytes is not fully understood. In the present study we investigated insulin-dependent mitochondrial Ca2+ signaling in normal and norepinephrine or insulin like growth factor-1-induced hypertrophic cardiomyocytes. Using mitochondrion-selective Ca2+-fluorescent probes we showed that insulin increases mitochondrial Ca2+ levels. This signal was inhibited by the pharmacological blockade of either the inositol 1,4,5-triphosphate receptor or the mitochondrial Ca2+ uniporter, as well as by siRNA-dependent mitochondrial Ca2+ uniporter knockdown. Norepinephrine-stimulated cardiomyocytes showed a significant decrease in endoplasmic reticulum-mitochondrial contacts compared to either control or insulin like growth factor-1-stimulated cells. This resulted in a reduction in mitochondrial Ca2+ uptake, Akt activation, glucose uptake and oxygen consumption in response to insulin. Blocking mitochondrial Ca2+ uptake was sufficient to mimic the effect of norepinephrine-induced cardiomyocyte hypertrophy on insulin signaling. Mitochondrial Ca2+ uptake is a key event in insulin signaling and metabolism in cardiomyocytes.


  • Open Access

    Mitochondrial fission is required for cardiomyocyte hypertrophy via a Ca2+-calcineurin signalling pathway

    by Christian Pennanen, Valentina Parra, Camila López-Crisosto, Pablo E. Morales, Andrea del Campo, Tomás Gutierrez, Pablo Rivera-Mejías, Jovan Kuzmicic, Mario Chiong, Antonio Zorzano, et al.

    Cardiomyocyte hypertrophy has been associated with diminished mitochondrial metabolism. Mitochondria are crucial organelles for the production of ATP, and their morphology and function are regulated by the dynamic processes of fusion and fission. The relationship between mitochondrial dynamics and cardiomyocyte hypertrophy is still poorly understood. Here, we show that treatment of cultured neonatal rat cardiomyocytes with the hypertrophic agonist norepinephrine promotes mitochondrial fission (characterized by a decrease in mitochondrial mean volume and an increase in the relative number of mitochondria per cell) and a decrease in mitochondrial function. We demonstrate that norepinephrine acts through α1-adrenergic receptors to increase cytoplasmic Ca2+, activating calcineurin and promoting migration of the fission protein Drp1 (encoded by Dnml1) to mitochondria. Dominant-negative Drp1 (K38A) not only prevented mitochondrial fission, it also blocked hypertrophic growth of cardiomyocytes in response to norepinephrine. Remarkably, an antisense adenovirus against the fusion protein Mfn2 (AsMfn2) was sufficient to increase mitochondrial fission and stimulate a hypertrophic response without agonist treatment. Collectively, these results demonstrate the importance of mitochondrial dynamics in the development of cardiomyocyte hypertrophy and metabolic remodeling.


  • Mitochondrial fragmentation impairs insulin-dependent glucose uptake by modulating Akt activity through mitochondrial Ca2+ uptake

    by Andrea del Campo, Valentina Parra, César Vásquez-Trincado, Tomás Gutiérrez, Pablo E. Morales, Camila López-Crisosto, Roberto Bravo-Sagua, Mario F. Navarro-Marquez, Hugo E. Verdejo, Ariel Contreras-Ferrat, et al.

    Insulin is a major regulator of glucose metabolism, stimulating its mitochondrial oxidation in skeletal muscle cells. Mitochondria are dynamic organelles that can undergo structural remodeling in order to cope with these ever-changing metabolic demands. However, the process by which mitochondrial morphology impacts insulin signaling in the skeletal muscle cells remains uncertain. To address this question, we silenced the mitochondrial fusion proteins Mfn2 and Opa1 and assessed insulin-dependent responses in L6 rat skeletal muscle cells. We found that mitochondrial fragmentation attenuates insulin-stimulated Akt phosphorylation, glucose uptake and cell respiratory rate. Importantly, we found that insulin induces a transient rise in mitochondrial Ca2+ uptake, which was attenuated by silencing Opa1 or Mfn2. Moreover, treatment with Ruthenium red, an inhibitor of mitochondrial Ca2+ uptake, impairs Akt signaling without affecting mitochondrial dynamics. All together, these results suggest that control of mitochondrial Ca2+ uptake by mitochondrial morphology is a key event for insulin-induced glucose uptake.


  • Influence of glucose metabolism on vascular smooth muscle cell proliferation

    by Mario Chiong, Pablo E. Morales, Gloria Torres, Tomás Gutiérrez, Lorena García, Mauricio Ibacache, Luis Michea

    Differentiation of vascular smooth muscle cells (VSMC) is an essential process of vascular development. VSMC have biosynthetic, proliferative, and contractile roles in the vessel wall. Alterations in the differentiated state of the VSMC play a critical role in the pathogenesis of atherosclerosis and intimal hyperplasia, as well as in a variety of other human diseases, including hypertension, asthma, atherosclerosis and vascular aneurysm. This review provides an overview of the current state of knowledge of molecular mechanisms involved in controlling VSMC proliferation, with particular focus on glucose metabolism and its relationship with mitochondrial bioenergetics. Increased levels of glucose transporter 1 (GLUT1) are observed in VSMC after endothelial injury, suggesting a relationship between glucose uptake and VSMC proliferation. Mitochondrial dysfunction is a common feature in VSMC during atherosclerosis. Alterations in mitochondrial function can be produced by dysregulation of mitofusin-2, a small GTPase associated with mitochondrial fusion. Moreover, exacerbated proliferation was observed in VSMC from pulmonary arteries with hyperpolarized mitochondria and enhanced glycolysis/glucose oxidation ratio. Several lines of evidence highlight the relevance of glucose metabolism in the control of VSMC proliferation, indicating a new area to be explored in the control of vascular pathogenesis.


  • Mitochondria, Myocardial Remodeling, and Cardiovascular Disease

    by Hugo E. Verdejo, Andrea del Campo, Rodrigo Troncoso, Tomás Gutierrez, Barbra Toro, Clara Quiroga, Zully Pedrozo, Juan Pablo Munoz, Lorena Garcia, Pablo F. Castro, et al.

    The process of muscle remodeling lies at the core of most cardiovascular diseases. Cardiac adaptation to pressure or volume overload is associated with a complex molecular change in cardiomyocytes which leads to anatomic remodeling of the heart muscle. Although adaptive at its beginnings, the sustained cardiac hypertrophic remodeling almost unavoidably ends in progressive muscle dysfunction, heart failure and ultimately death. One of the features of cardiac remodeling is a progressive impairment in mitochondrial function. The heart has the highest oxygen uptake in the human body and accordingly it has a large number of mitochondria, which form a complex network under constant remodeling in order to sustain the high metabolic rate of cardiac cells and serve as Ca2+ buffers acting together with the endoplasmic reticulum (ER). However, this high dependence on mitochondrial metabolism has its costs: when oxygen supply is threatened, high leak of electrons from the electron transport chain leads to oxidative stress and mitochondrial failure. These three aspects of mitochondrial function (Reactive oxygen species signaling, Ca2+ handling and mitochondrial dynamics) are critical for normal muscle homeostasis. In this article, we will review the latest evidence linking mitochondrial morphology and function with the process of myocardial remodeling and cardiovascular disease.


  • Endoplasmic reticulum: ER stress regulates mitochondrial bioenergetics

    by Roberto Bravo, Tomás Gutierrez, Felipe Paredes, Damián Gatica, Andrea E. Rodriguez, Zully Pedrozo, Mario Chiong, Valentina Parra, Andrew F.G. Quest, Beverly A. Rothermel, et al.